Connect with us

Medical Research

FDA Gives Approval for Human Drug Trial on Effectiveness of Marijuana-Based Medicine

Published

on

FDA Gives Approval for Human Drug Trial on Effectiveness of Marijuana-Based Medicine

According to a recent report by Connecticut Public Radio, a study will take place to determine the effects of medical marijuana.

The Yale School of Medicine and CT Pharma, a medical marijuana supplier, will conduct human trials, which have been given the green light by the Food and Drug Administration. The trial’s lead investigator, Dr. Rajita Sinha of the Yale School of Medicine, shared in the report that she hopes that the results will provide true scientific answers to a range of questions on medical marijuana.

For instance, she hopes that it will reveal how marijuana works, who it works for, the necessary doses, the symptoms that can be alleviated, and if there is a need for refinement. The research study will feature a double-blind placebo-controlled method. One group will receive an oral tablet of medical marijuana from CT pharma, while a second group will receive a placebo.

Michael Fedel, the board chair of CT Pharma, shared with reporters that he hopes that the study will yield the first medical marijuana-based medicine approved by the FDA and manufactured in the United States. At this point, the only FDA-approved plant-based medical marijuana CBD company product is made in England.

News station KYMA also reported that Yale indicated that the first phase will include men and women between the ages of 21 and 45, and who are recreational marijuana users. This group does not qualify for medical cannabis use. As for the second phase, it will include men and women from 21 to 61 who suffer from chronic pain. Not only will the effects of marijuana be studied, but so will potential side effects, such as heart rate, diastolic blood pressure, and other clinical symptoms.

Cheryl Anne hails from Great Britain and casts a large shadow with her master’s degree in Relationship Therapy as well as a number of other professional accreditations. While she specializes in psychological thrillers and self-help books, her undeniable and uncanny knack for sifting through the cracks of the cannabis and CBD space are extremely necessary and sought after.

Continue Reading

Ultimate CBD Guide


Disclaimer

ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email contact@timesofcbd.com

Copyright © 2020 TimesofCBD.com | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.